Emerging and Evolving Biomarkers: HRD Score
This content was created in 2020, but has been reviewed and approved by the Training & Education Committee as useful, accurate, and relevant. Please note that in the time since this material was posted, there may have been additional developments, advancements, and/or more current publications in this field.
AMP Education is constantly updating our educational offerings, and will remove or replace content that is no longer accurate. Please be sure to use the search function to find related or updated material available in our catalogue at educate.amp.org. The Training and Education Committee works with AMP Education Programs to bring you the most up-to-date and cutting-edge information on molecular pathology research, applications, and training.
This webinar does not contain continuing education credit (CME and CMLE)
 |
 |
|---|---|
|
Speaker: Melinda Telli, MD |
Moderator: Kurtis Davies, PhD |
This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and the audience QA.
Description:
Homologous recombination deficiency score (HRD) includes assessment of loss of heterozygosity, large-scale state transitions, and telomeric allelic imbalance as an assessment of functional loss of homologous recombination repair. HRD score has been studied in multiple tumor types with the aim of predicting therapeutic response independent of homologous recombination repair gene mutation status. The scientific background, testing considerations, and clinical implications will be discussed in this presentation.
Learning Objectives:
1. Describe the biological principles that underlie the relevance of HRD score, including the cellular signaling pathways and cellular processes involved.
2. Discuss the appropriate technical approaches and platforms for HRD score molecular diagnostic testing.
3. Outline the strengths and limitations of described testing approaches.
4. Apply HRD score information so as to order appropriate testing and interpret test results within a clinical context.
This webinar is part 2 of the Emerging and Evolving Biomarkers Series.
Recorded Date: July 21, 2020
Duration: 1 hr
Level of Instruction: Basic
This webinar does not contain continuing education credit (CME and CMLE)
AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC. IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.
Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.
Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.